As of May 31, 2025, Sigilon Therapeutics Inc (SGTX) reports a Current Ratio of 2.40.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Sigilon Therapeutics Inc's Current Ratio
Over recent years, Sigilon Therapeutics Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2022-12-31 | 2.40 |
| 2021-12-31 | 3.62 |
| 2020-12-31 | 4.34 |
| 2019-12-31 | 1.91 |
| 2018-12-31 | 2.21 |
This gradual decrease highlights how Sigilon Therapeutics Inc manages its short-term assets and liabilities over time.
Comparing Sigilon Therapeutics Inc's Current Ratio to Peers
To better understand Sigilon Therapeutics Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Sigilon Therapeutics Inc (SGTX) | 2.40 |
| Dyne Therapeutics Inc (DYN) | 15.60 |
| IDEAYA Biosciences Inc (IDYA) | 14.97 |
| Akouos Inc (AKUS) | 14.06 |
| Oric Pharmaceuticals Inc (ORIC) | 10.55 |
| Prothena Corporation PLC (PRTA) | 10.01 |
Compared to its competitors, Sigilon Therapeutics Inc's Current Ratio is among the lowest compared to peers, suggesting tighter liquidity management or potential short-term obligations concerns.